Enteroclostridium casseliflavum strain and application thereof

Abstract

The present application belongs to the field of microbial technology, and is a duck-derived Enterococcus coli strain and its application. The Enterococcus coli provided in the present application is Enterococcus coli (Enterococcus coli) Collinsella intestinalis ) with strain number ZW01, and the registration number in the China General Microbiological Culture Collection Center is CGMCC No. 46915. The preservation address is No. 3, Xili, Beichen, Beijing, and the preservation date is January 23, 2026. The strain ZW01 of the present application can improve the feed conversion efficiency of Beijing ducks, reduce the abdominal fat rate of Beijing ducks, and reduce the content of triglyceride in the plasma and liver of Beijing ducks. The strain can also reduce the brown fat weight, inguinal fat weight, epididymal fat weight, brown fat index, inguinal fat index and epididymal fat index of mice under a high-fat diet, and improve the gastrocnemius index of mice, and has a good development and application prospect.

Description

Technical Field

[0001] This application belongs to the field of microbial technology, specifically relating to a duck-derived Enterocytobacter bacterium strain and its application. Background Technology

[0002] Improving feed conversion efficiency in broiler ducks is beneficial for reducing breeding costs and increasing breeding efficiency. Fat deposition is highly correlated with feed conversion efficiency and is an important economic trait in broiler duck production. Feed conversion efficiency, as a complex trait, is affected by factors such as genetics, nutrition, disease, and environment.

[0003] Currently, the gut microbiota is believed to play a crucial role in the digestion and absorption of nutrients in livestock and poultry, influencing fat deposition and feed conversion efficiency. Most probiotics currently used as feed additives are non-duck derived, which may negatively impact the balance of the gut microbiota in broiler ducks. Therefore, there is an urgent need to develop and study gut microbiota isolated from broiler ducks to further improve their feed conversion efficiency. Summary of the Invention

[0004] The technical problem to be solved by this invention is how to improve the digestion and absorption of nutrients by livestock and poultry, thereby regulating fat deposition and improving feed conversion efficiency.

[0005] To solve the above-mentioned technical problems, the present invention first provides a strain of Enterococcus faecalis (… Collinsella intestinalis ).

[0006] The Enterocytobacter spp. provided by this invention ( Collinsella intestinalis The strain, ZW01, is registered at the China General Microbiological Culture Collection Center (CGMCC) under the number CGMCC No. 46915. This strain was deposited on January 23, 2026, at CGMCC, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, 100101, China. It will be referred to as *Enteromorpha enterica* below.

[0007] When *Colinella enterica* was grown anaerobically on GAM solid medium at 37°C for 48 hours, the colonies were round, approximately 1 mm in diameter, milky white, with a smooth, slightly upward-convex surface and smooth, regular edges. The *Colinella enterica* strain possessed 16S rDNA containing the sequence shown in SEQ ID NO:1.

[0008] Cultures of Enterococcus faecalis are also within the scope of protection of this invention.

[0009] In the above text, the culture of *Colinella enterica* is a substance obtained by culturing *Colinella enterica* in a microbial culture medium (such as a substance containing *Colinella enterica* and secreted into the culture medium). The microbial culture medium may be GAM agar solid medium, and the culture may be carried out in an anaerobic environment at 37°C.

[0010] To address the above technical problems, the present invention also provides a microbial agent. The microbial agent contains the aforementioned *Enterococcus enterica* and / or a culture of the aforementioned *Enterococcus enterica*.

[0011] The active ingredient of the above-mentioned bacterial agent may be the above-mentioned Enterococcus or / and the above-mentioned Enterococcus culture. The active ingredient of the above-mentioned bacterial agent may also contain other biological or non-biological components. Other active ingredients of the above-mentioned bacterial agent can be determined by those skilled in the art based on the effect of the bacterial agent.

[0012] The microbial agent may also include a carrier. The carrier may be a solid carrier or a liquid carrier.

[0013] In the bacterial agent, the above-mentioned Enterococcus and / or the culture of the above-mentioned Enterococcus can exist in the form of cultured live cells.

[0014] The microbial agent can be in various formulations, such as liquid, emulsion, suspension, powder, granules, wettable powder or water-dispersible granules.

[0015] To address the aforementioned technical problems, the present invention also provides at least one application of the above-mentioned Enterococcus faecalis, or a culture of the above-mentioned Enterococcus faecalis, or the above-mentioned bacterial agent: B1) Application in improving feed conversion efficiency in ducks and / or in the preparation of products that improve feed conversion efficiency in ducks; B2) Application in reducing abdominal fat percentage in ducks and / or in the preparation of products that reduce abdominal fat percentage in ducks; B3) Application in reducing the triglyceride content in duck plasma and / or in the preparation of products that reduce the triglyceride content in duck plasma; B4) Application in reducing the triglyceride content in duck liver and / or in the preparation of products that reduce the triglyceride content in duck liver; B5) Application in reducing fat quality and fat content in mice on a high-fat diet and / or in the preparation of products that reduce fat quality and fat content in mice on a high-fat diet; B6) Use in reducing brown adipose mass, inguinal adipose mass, epididymal adipose mass, brown adipose index, inguinal adipose index and epididymal adipose index in mice on a high-fat diet, and / or in the preparation of products that reduce brown adipose mass, inguinal adipose mass, epididymal adipose mass, brown adipose index, inguinal adipose index and epididymal adipose index in mice on a high-fat diet. B7) Application in increasing the gastrocnemius muscle index in mice on a high-fat diet and / or in the preparation of products that increase the gastrocnemius muscle index in mice on a high-fat diet.

[0016] In one embodiment of the present invention, the duck is a Beijing duck.

[0017] In the applications described above, the product may be feed or medicine.

[0018] The method for culturing the aforementioned Enterocolinella is also within the scope of protection of this invention.

[0019] The method for culturing the Enterocolinella provided by the present invention includes the step of culturing the Enterocolinella in a culture medium.

[0020] The method for preparing the bacterial agent is also within the scope of protection of this invention.

[0021] The method for preparing the bacterial agent provided by the present invention includes the step of anaerobic culture of the Enterococcus faecium in a microbial culture medium. The microbial culture medium may be GAM liquid medium.

[0022] The Enterocytobacter ZW01 strain of the present invention ( Collinsella intestinalis This strain belongs to the duck-derived Colinella species. The Colinella enterica strain ZW01 of this invention can improve feed conversion efficiency in Beijing ducks, reduce abdominal fat percentage, and decrease triglyceride levels in plasma and liver. This strain can also reduce brown fat weight, groin fat weight, epididymal fat weight, brown fat index, groin fat index, and epididymal fat index in mice on a high-fat diet, and increase the gastrocnemius muscle index in mice.

[0023] Preservation Instructions Classification and nomenclature: Enterocolinella Collinsella intestinalis Latin scientific name: Collinsella intestinalis Strain number: ZW01 Full name of the depository: China General Microbiological Culture Collection Center, China Microbiological Culture Collection Committee Abbreviation of depositary institution: CGMCC Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing; Postcode: 100101; Deposit date: January 23, 2026; Accession number: CGMCC No.46915. Attached Figure Description

[0024] Figure 1 The Enterocytobacter spp. in Example 1 of this invention ( Collinsella intestinalis 48h growth curve.

[0025] Figure 2 The Enterocytobacter spp. in Example 1 of this invention ( Collinsella intestinalis ) Colony morphology.

[0026] Figure 3 This is the 24-hour growth curve of *Colinella enterica* in Example 1 of the present invention, measured against different pH values.

[0027] Figure 4 To illustrate the temperature tolerance of *Colinella enterica* in Example 1 of this invention, OD values ​​at t=0 and 12h were measured. 600 value.

[0028] Figure 5 This is a growth performance diagram of the Beijing duck in Embodiment 2 of the present invention, wherein, Figure 5 Figure A in the chart shows the weight of a 1-day-old Beijing duck. Figure 5 Figure B in the chart shows the weight of a 14-day-old Beijing duck. Figure 5 Figure C in the diagram; weight of a 42-day-old Beijing duck; Figure 5 Figure D in the diagram shows the feed consumption of a single duck aged 15-42 days. Figure 5 Figure E in the diagram shows the feed weight ratio for feed aged 15-42 days. * indicates a significant difference in the analysis results. P <0.05.

[0029] Figure 6 This is a diagram showing the slaughter performance of the Beijing duck in Embodiment 2 of the present invention, wherein, Figure 6 Figure A in the diagram: Sebum percentage; Figure 6 Figure B in the diagram shows the abdominal fat percentage.

[0030] Figure 7 The content of triglycerides in the plasma of Beijing ducks in Example 2 of this invention is shown. ** indicates a significant difference in the analysis results. P <0.01.

[0031] Figure 8 The content of triglycerides in the liver of Beijing ducks in Example 2 of this invention is given. ** indicates a significant difference in the analysis results. P <0.01.

[0032] Figure 9 This shows the body weight and feed consumption of the mice in Example 3 of the present invention during the experimental period. Among them, Figure 9 Figure A in the diagram: Body weight of 0w mice; Figure 9 Figure B in the figure shows the body weight of a 17-week-old mouse. Figure 9 Figure C in the table shows the weekly feed consumption of a single cage of mice. Here, ns represents no significant difference, and ** indicates a negative result from the significance analysis. P <0.01, *** represents the result of the significance analysis. P <0.001.

[0033] Figure 10The results of body composition analysis of the experimental mice in Example 3 of this invention are shown below. Figure 10 Figure A in the figure: Lean meat mass in mice; Figure 10 Figure B in the diagram: Lean meat content in mice; Figure 10 Figure C in the diagram: Mouse fat mass; Figure 10 Figure D in the diagram shows the body fat percentage in mice. * indicates a significant result from the analysis. P <0.05, ** indicates the significance analysis result is... P <0.01, *** represents the result of the significance analysis. P <0.001.

[0034] Figure 11 The figures show the weight and relative content of three types of adipose tissue in the experimental mice used in Example 3 of this invention. Figure 11 Figure A in the diagram shows the weight of brown adipose tissue in mice. Figure 11 Figure B in the image shows the groin fat weight of mice. Figure 11 Figure C in the diagram shows the epididymal fat weight in mice. Figure 11 Figure D in the diagram: Brown fat index in mice; Figure 11 Figure E in the figure represents the inguinal fat index of mice. Figure 11 Figure F in the figure: Epididymal fat index in mice. * indicates the result of the significance analysis. P <0.05, ** indicates the significance analysis result is... P <0.01, *** represents the result of the significance analysis. P <0.001, **** represents the significance analysis result. P <0.0001.

[0035] Figure 12 The figures represent the weight and relative content of the gastrocnemius muscle of the experimental mice in Example 3 of this invention. Figure 11 Figure A in the diagram shows the weight of the gastrocnemius muscle. Figure 11 Figure B in the diagram shows the gastrocnemius muscle index. **** represents the significance analysis result. P <0.0001. Detailed Implementation

[0036] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0037] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.

[0038] In the following examples, unless otherwise specified, the first position of each nucleotide sequence in the sequence listing is the 5' terminal nucleotide of the corresponding DNA / RNA, and the last position is the 3' terminal nucleotide of the corresponding DNA / RNA.

[0039] In the following examples, the Beijing duck is described in the literature “Gao Kexin, Zhang Bo, Sun Weili, et al. Study on 25-hydroxyvitamin D3 and vitamin D3 requirements and their relative biological efficacy in 14-35 day old Beijing ducks [J]. Chinese Journal of Animal Nutrition, 2023, 35(5):3014-3024.” The public can obtain the test results from the applicant to repeat the test results of this application.

[0040] The Enterocytobacter ZW01 strain of the present invention ( Collinsella intestinalis The strain was classified and named Enterocolinella. Collinsella intestinalis The strain was deposited on January 23, 2026, at the China General Microbiological Culture Collection Center (CGMCC, address: No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, 100101, China), with accession number CGMCC No. 46915.

[0041] Example 1 Enterococcus faecalis ( Collinsella intestinalis Isolation of strains 1. Strains isolated: Enterocolinella ( Collinsella intestinalis The bacteria were isolated from the cecal contents of Beijing ducks in February 2025. Cecal segments were removed from slaughtered Beijing ducks, tied with sterile nylon rope, and placed on ice. Within 2 hours, they were transferred to an anaerobic incubator to extract the cecal contents. The contents were serially diluted 10-fold with sterile physiological saline. 0.1 mL of the appropriate concentration of the diluted solution was evenly spread on GAM (Gifu Anaerobic Medium Agar) and incubated at 37°C for 48 hours anaerobic. Single colonies from the plates were picked, streaked onto another new GAM solid medium, and purified and cultured for 48 hours.

[0042] 2. Enrichment of bacterial strains: After purification and culture, the bacterial strains were further cultured on GAM solid plates in an anaerobic incubator using an inoculation loop. After 48 hours of further culture in an anaerobic incubator, an appropriate amount of colonies were picked for 16S rRNA identification. The remaining bacterial cells were scraped off and mixed with 25% sterile glycerol. After vortexing and mixing, the mixture was stored at -80℃.

[0043] 3. Detection of physiological and biochemical characteristics The physiological and biochemical characteristics of a strain ZW01 purified in this invention were analyzed: 3.1 Growth curve determination The strain ZW01 of this invention was cultured until its concentration reached 2×10⁻⁶. 8CFU / mL of bacterial culture was inoculated into pre-deoxygenated GAM liquid medium at a volume of 2%. The OD value of the medium was measured every 3-4 hours using a microplate reader. 600 The value of .

[0044] The results show that ( Figure 1 This strain reaches the logarithmic growth phase after 12 hours, the plateau phase after 20 hours, and the maximum viable count reaches 3.6 × 10⁻⁶. 8 CFU / mL.

[0045] 3.2 Colony morphology: Round single colonies, approximately 1 mm in diameter, milky white, with a smooth, slightly upward-convex surface and smooth, regular edges. Figure 2 ).

[0046] 3.3. Tolerance to different pH levels The activated bacterial culture concentration is 2×10⁻⁶. 8 ZW01 bacterial suspension with CFU / mL was inoculated at a rate of 4% (400 μL) into pre-deoxygenated GAM liquid medium at pH 2, 3, 4, 5, 6, and 6.8 (CON group). Growth curves were measured after 24 hours. The results showed that... Figure 3 At pH=6, the growth of strain ZW01 of this invention is not affected.

[0047] 3.4. Resistance to different temperatures (tested) The activated bacterial culture concentration is 2×10⁻⁶. 8 The bacterial suspension of strain ZW01 of this invention, at a concentration of CFU / mL, was inoculated into pre-deoxygenated GAM liquid medium at a 4% inoculation rate of 400 μL. The inoculated medium was then placed in water baths at 30°C, 37°C, 40°C, 50°C, 60°C, and 70°C for 15 min, respectively. After cooling to room temperature, the medium was transferred to a standard 37°C incubator. The OD values ​​of the culture medium were measured using a microplate reader at t=0 h and 12 h. 600 The value, the result shows ( Figure 4 With the 37℃ group as the control, the growth of Enterococcus strain ZW01 was not affected by water bath temperatures of 30℃, 40℃ and 50℃.

[0048] 4. 16S rRNA identification: Colonies cultured on GAM medium were amplified by PCR using universal bacterial primers, followed by 16S rDNA sequencing. Sequence alignment was performed on the EzBioCloud database (https: / / www.ezbiocloud.net / identify). The sequence similarity was 98.25%, confirming that strain ZW01 of this invention is *Enterococcus enterica*. Collinsella intestinalisThe bacterial strain was subjected to third-generation sequencing and genome assembly, and the 16S rDNA sequence was determined as shown in SEQ ID NO:1.

[0049] SEQ ID NO:1 Example 2 Enterococcus faecalis ( Collinsella intestinalis Effects of strain ZW01 on feed conversion efficiency and lipid metabolism in Beijing ducks I. Experimental Methods 1. Eighty one-day-old Beijing ducks were selected and raised at the Changping Base of the Beijing Institute of Animal Husbandry and Veterinary Medicine, Chinese Academy of Agricultural Sciences. The ducks were raised on wire mesh flooring and had free access to feed and water during the experiment. They were provided with 24-hour light and other routine feeding and management practices. From 1 to 14 days of age, the Beijing ducks were placed in the brooding room, and from 15 to 42 days of age, they were transferred to the feed conversion efficiency testing room and fed individually in cages.

[0050] 2. All Peking ducks were randomly divided into two groups (40 Peking ducks in each group): control group and Enterococcus faecalis group.

[0051] Centrifuge the cultured bacterial culture, discard the supernatant, resuspend in sterile 1×PBS buffer, and adjust the bacterial concentration to 2×10⁻⁶. 8 CFU / kg body weight, administered via gavage every morning. The control group received the same volume of sterile 1×PBS buffer via gavage daily. Gavage was continued from day 1 to day 42.

[0052] II. Detection Indicators 1. During the experiment, the body weight of 1-day-old, 14-day-old and 42-day-old ducks, the feed intake of 15-42-day-old Beijing ducks, and the feed conversion ratio of 15-42-day-old ducks were measured.

[0053] 2. Determine the skin fat percentage and abdominal fat percentage of Peking ducks. After the experiment, the experimental ducks were fasted for 6 hours and their weight was recorded as their weight at 42 days of age. Subcutaneous fat weight: The skin and subcutaneous fat of the tested ducks were removed, and the weight of the subcutaneous fat was measured. Abdominal fat weight: The abdominal fat and fat around the gizzard of the test ducks were removed and the abdominal fat was weighed.

[0054] The skin fat percentage and abdominal fat percentage of Beijing ducks are calculated according to formula (1) and formula (2), respectively.

[0055] Sebum rate = sebum weight / body weight at 42 days of age × 100% formula (1).

[0056] Abdominal fat rate = abdominal fat weight / body weight at 42 days of age × 100% formula (2).

[0057] 3. Determination of triglyceride content in Beijing duck plasma At 42 days of age, after fasting the experimental ducks for 6 hours, 5 mL of blood was collected from the subwing vein and placed in a blood collection tube containing heparin sodium anticoagulant. Plasma was prepared by centrifugation at 4°C and 3000 r / min for 10 min. The triglyceride (TG) assay was performed using a triglyceride kit (CH0101151, Sinopharm Biotech Co., Ltd.) on a Hitachi 721 fully automated biochemical analyzer.

[0058] 4. Determination of triglyceride content in the liver of Beijing ducks Liver triglycerides were quantified using the CheKine™ Triglyceride (TG) Detection Kit (KTB2200, Acine Biotech Ltd.), and protein was quantified using the Rapid Protein Quantification Kit (KTD3010-CN, Acine Biotech Ltd.). The triglyceride content was quantified per unit protein in liver tissue.

[0059] III. Test Results Growth performance data: such as Figure 5 As shown in Figure A, there was no significant difference in the body weight of 1-day-old Peking ducks in the *Enterococcus faecium* group compared to the control group; Figure 5 As shown in Figure B, there was no significant difference in body weight of 14-day-old Peking ducks in the *Enterococcus faecium* group compared to the control group; Figure 5 As shown in Figure C, there was no significant difference in body weight of 42-day-old Peking ducks in the *Enterococcus faecium* group compared to the control group; Figure 5 As shown in Figure D, compared with the control group, the gavage administration of Enterococcus faecalis (D) Collinsella intestinalis It had no significant effect on feed consumption in Beijing ducks aged 15-42 days; Figure 5 As shown in Figure E. Gavage administration of Enterococcus faecalis (Gastrointestinal Collins) Collinsella intestinalis It significantly reduced the feed conversion ratio of Beijing ducks aged 15-42 days.

[0060] like Figure 6 As shown in Figure A, oral administration of Enterococcus faecalis (C. faecalis) Collinsella intestinalis It had no significant effect on the skin fat percentage of 42-day-old Beijing ducks. Figure 6 As shown in Figure B, oral administration of Enterococcus faecalis (Gastrointestinal Collins) Collinsella intestinalis There is a trend of reducing abdominal fat percentage in 42-day-old Beijing ducks.

[0061] like Figure 7 As shown, Enterococcus faecalis was administered via gavage. Collinsella intestinalis It significantly reduced the triglyceride (TG) content in the plasma of 42-day-old Beijing ducks.

[0062] like Figure 8 As shown, oral administration of Enterococcus faecalis (C. faecalis) Collinsella intestinalis It significantly reduced the triglyceride (TG) content in the liver of 42-day-old Beijing ducks.

[0063] Example 3 Enterococcus faecalis ( Collinsella intestinalis Effects of high-fat diet intervention on alleviating obesity in mice I. Experimental Methods Forty-two four-week-old male C57BL6J mice (B204, a product of Spifor (Beijing) Biotechnology Co., Ltd.) were selected. During the experiment, the temperature of the mouse room was controlled at 22±2℃, the light / dark period was 12 hours, and the mice were allowed free access to food and water. They were acclimatized for 2 weeks before the experiment.

[0064] All mice were divided into 14 cages (3 mice per cage): low-fat control group (NC group), high-fat diet group (HFD group), high-fat diet group + gavage with Enterobacter cylindrica (NC) group, and high-fat diet group + gavage with Enterobacter cylindrica (NC) group. Collinsella intestinalis Group (HFD+CI group).

[0065] Mice in the NC group were allowed free access to a 10% fat-based functional purified diet (D12450B) (a product of SPEF (Beijing) Biotechnology Co., Ltd.) during the experimental period. Mice in the HFD and HFD+CI groups were allowed free access to a 60% fat-based energy-providing diet (D12492) (a product of SPEF (Beijing) Biotechnology Co., Ltd.) during the experimental period. Mice in the HFD+CI group were administered 1×10⁻⁶ mg / L via gavage every other day. 9 CFU / mL Collinsella intestinalis 100 μL of bacterial culture (1 × 10 9 CFU / mL Collinsella intestinalis The bacterial solution was prepared at a concentration of 1.25 × 10⁻⁶. 10 CFU / mL Collinsella intestinalis The bacterial culture was prepared by diluting sterile PBS 12.5 times (the bacterial culture administered by gavage contained 1.6% glycerol), and the sterile PBS administered by gavage to the NC and HFD groups contained 1.6% glycerol.

[0066] II. Detection Indicators 1. During the experiment, the initial body weight and body weight at the end of the experiment, as well as the amount of food consumed, were recorded.

[0067] 2. One week before the end of the experiment, the body composition of the mice was measured. The measurement method was based on the method in "Tan Mingqian, Lin Zhuyi, Li Chenyang, et al. Development of non-destructive analysis method for mouse body composition based on low field nuclear magnetic resonance technology [J]. Journal of Analytical Science, 2018, 34(4):463-470.DOI:10.13526 / j.issn.1006-6144.2018.04.004."

[0068] 3. Statistical analysis of organ indices in mice. Mice were fasted for 4-6 hours and weighed. After euthanizing the mice, brown fat, inguinal fat, epididymal fat, and gastrocnemius muscle were quickly removed and weighed fresh. The formula for calculating the mouse organ index is formula (3): Organ index = (organ wet weight / mouse body weight) × 100% Formula (3).

[0069] III. Test Results 1. Growth status: The growth status of the mice throughout the experiment is as follows: Figure 9 As shown, Figure 9 Figure A in the figure shows that there was no significant difference in the body weight of the mice at the beginning of the experiment (0w), as shown in Figure A. Figure 9 Figure B in the figure shows that, compared with the HFD group, the HFD+CI group mice had no significant difference in body weight at 17 weeks. Figure 9 Figure C in the figure shows that there was no significant difference in weekly feed consumption per cage among mice in the HFD+CI group compared to the HFD group.

[0070] 2. Body composition results as follows Figure 10 As shown, where Figure 10 Figure A in the diagram represents the lean meat mass of mice. Figure 10 Figure B in the graph shows the lean meat content of the mice. Figure 10 Figure C in the figure shows that the fat mass of mice in the HFD+CI group was significantly reduced compared with the HFD group. Figure 10 The D-plot in the figure shows that the fat content of mice in the HFD+CI group was significantly lower than that in the HFD group. 3. Organ index of mice, such as Figure 11 As shown: Figure 11 Figure A in the figure shows that the brown adipose tissue mass of mice in the HFD+CI group was significantly reduced compared to the HFD group. Figure 11 Figure B in the figure shows that the inguinal fat mass of mice in the HFD+CI group was significantly reduced compared with that in the HFD group. Figure 11 Figure C in the diagram shows that, compared to the HFD group, the epididymal fat mass of mice in the HFD+CI group tended to decrease. Figure 11 The D diagram shows that the brown adipose tissue index of mice in the HFD+CI group was significantly lower than that in the HFD group. Figure 11 Figure E in the figure shows that the inguinal fat index of mice in the HFD+CI group was significantly lower than that in the HFD group. Figure 11 The F-plot in the figure shows that the epididymal fat index of mice in the HFD+CI group was significantly reduced compared with that in the HFD group.

[0071] 4. The gastrocnemius muscle weight and gastrocnemius muscle index of the experimental mice are as follows: Figure 12 As shown: Figure 12 Figure A in the figure shows that, compared with the HFD group, the gastrocnemius muscle weight of mice in the HFD+CI group was not significantly affected. Figure 12Figure B in the figure shows that the gastrocnemius muscle index of mice in the HFD+CI group was significantly increased compared with that in the HFD group.

[0072] The above results demonstrate that the duck-derived Enterocytobacter bacterium of the present invention can improve the feed conversion efficiency of Beijing ducks, reduce the abdominal fat rate of Beijing ducks, and reduce the triglyceride content in the plasma and liver of Beijing ducks. This strain can also reduce brown fat weight, groin fat weight, epididymal fat weight, brown fat index, groin fat index and epididymal fat index in mice under a high-fat diet, and increase the gastrocnemius muscle index in mice.

[0073] The present invention has been described in detail above. Those skilled in the art will recognize that the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. While specific embodiments have been provided, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein.

Claims

1. Enterococcus faecalis, characterized by: The Enterocolinella species mentioned are Enterocolinella (… Collinsella intestinalis The strain number is ZW01, and its registration number at the China General Microbiological Culture Collection Center is CGMCC No. 46915. The deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the deposit date is January 23, 2026.

2. A culture of Enterococcus faecalis, characterized in that: The culture is a substance obtained by culturing the Enterococcus faecium of claim 1 in a microbial culture medium.

3. A microbial agent, characterized in that: The bacterial agent contains the Enterococcus faecium as described in claim 1.

4. At least one of the following applications of the Enterococcus faecium according to claim 1: B1) Application in improving feed conversion efficiency in ducks and / or in the preparation of products that improve feed conversion efficiency in ducks; B2) Application in reducing abdominal fat percentage in ducks and / or in the preparation of products that reduce abdominal fat percentage in ducks; B3) Application in reducing the triglyceride content in duck plasma and / or in the preparation of products that reduce the triglyceride content in duck plasma; B4) Application in reducing the triglyceride content in duck liver and / or in the preparation of products that reduce the triglyceride content in duck liver; B5) Application in reducing fat quality and fat content in mice on a high-fat diet and / or in the preparation of products that reduce fat quality in mice on a high-fat diet; B6) Use in reducing brown adipose mass, inguinal adipose mass, epididymal adipose mass, brown adipose index, inguinal adipose index and epididymal adipose index in mice on a high-fat diet, and / or in the preparation of products that reduce brown adipose mass, inguinal adipose mass, epididymal adipose mass, brown adipose index, inguinal adipose index and epididymal adipose index in mice on a high-fat diet. B7) Application in increasing the gastrocnemius muscle index in mice on a high-fat diet and / or in the preparation of products that increase the gastrocnemius muscle index in mice on a high-fat diet.

5. The application according to claim 4, characterized in that: The duck in question is the Beijing duck.

6. The application according to claim 4 or 5, characterized in that: The product is either animal feed or medicine.

7. At least one of the following applications of the microbial agent according to claim 3: B1) Application in improving feed conversion efficiency in ducks and / or in the preparation of products that improve feed conversion efficiency in ducks; B2) Application in reducing abdominal fat percentage in ducks and / or in the preparation of products that reduce abdominal fat percentage in ducks; B3) Application in reducing the triglyceride content in duck plasma and / or in the preparation of products that reduce the triglyceride content in duck plasma; B4) Application in reducing the triglyceride content in duck liver and / or in the preparation of products that reduce the triglyceride content in duck liver; B5) Application in reducing fat quality and fat content in mice on a high-fat diet and / or in the preparation of products that reduce fat quality and fat content in mice on a high-fat diet; B6) Use in reducing brown adipose mass, inguinal adipose mass, epididymal adipose mass, brown adipose index, inguinal adipose index and epididymal adipose index in mice on a high-fat diet, and / or in the preparation of products that reduce brown adipose mass, inguinal adipose mass, epididymal adipose mass, brown adipose index, inguinal adipose index and epididymal adipose index in mice on a high-fat diet. B7) Application in increasing the gastrocnemius muscle index in mice on a high-fat diet and / or in the preparation of products that increase the gastrocnemius muscle index in mice on a high-fat diet.

8. The application according to claim 7, characterized in that: The duck in question is the Beijing duck.

9. The application according to claim 7 or 8, characterized in that: The product is either animal feed or medicine.

10. A method for preparing the microbial agent according to claim 3, characterized in that: The method includes the step of anaerobic culturing the Enterocytobacter spp. of claim 1 in a microbial culture medium.

Images